Table 1 Comparisons of clinical baseline characteristics in those with and without RRF
Parameter | RRF present | RRF absent | P-value | ||
|---|---|---|---|---|---|
Number of patients | 36 | 64 | – | ||
Age in years, mean ± SD | 37.4 | ±10.7 | 43 | ±10.2 | 0.01 |
Sex, n (%) | |||||
Male | 15 | (41.7) | 28 | (43.8) | 0.84 |
Female | 21 | (58.3) | 36 | (56.3) | |
Race, n (%) | |||||
Mixed ancestry | 23 | (63.9) | 42 | (65.6) | 0.15 |
Caucasian | 6 | (16.7) | 16 | (25.0) | |
Black | 5 | (13.9) | 6 | (9.4) | |
Indian | 2 | (5.6) | 0 | (0) | |
Underlying kidney disease, n (%) | |||||
ESKD (cause unknown) | 23 | (63.9) | 43 | (67.2) | 0.78 |
Renal vascular disease | 6 | (16.7) | 8 | (12.5) | |
Cystic kidney disease | 1 | (2.8) | 3 | (4.7) | |
Autoimmune disease | 2 | (5.6) | 2 | (3.1) | |
Other and unknown | 4 | (11.1) | 8 | (12.5) | |
Mode of dialysis, n (%) | |||||
HD | 15 | (41.7) | 52 | (81.3) | <0.01 |
PD | 21 | (58.3) | 12 | (18.8) | |
Dialysis vintage (months) | 34 | (10.5–53) | 64 | (41–125) | <0.01 |
ESA dose (IU per week) | 6000 | (5000–6000) | 6000 | (3000–9000) | 0.46 |
Route of ESA administration, n (%) | |||||
SC | 36 | (100) | 64 | (100) | – |
Chronic medication, n (%) | |||||
RAS blocker | 14 | (38.9) | 38 | (59.4) | 0.05 |
Diuretic | 27 | (75.0) | 20 | (31.3) | <0.01 |
Phosphate binder | 34 | (94.4) | 47 | (73.4) | 0.01 |
Vitamin D | 9 | (25.0) | 27 | (37.5) | 0.08 |
Iron therapy | 35 | (97.2) | 63 | (98.4) | 0.46 |
Oral | 31 | (86.1) | 50 | (78.1) | |
IV | 4 | (11.1) | 13 | (20.3) | |
Laboratory parameters | |||||
Haemoglobin (g/dL) | 10.1 | (9.2–11.1) | 10.1 | (8.8–10.8) | 0.54 |
Albumin (g/L) | 39 | (34–40) | 37 | (33–40) | 0.28 |
Ferritin (ng/mL) | 545.0 | (299–759.5) | 469.0 | (237.5–781.5) | 0.99 |
Transferrin saturation (%) | 22 | (15–30) | 23 | (16–29) | 0.49 |
CRP (mg/L) | 15 | (4–29) | 20 | (4–45) | 0.48 |
PTH (pmol/L) | 41.5 | (18.6–73.2) | 50.2 | (17.6–117.4) | 0.70 |
Systemic inflammation, n (%) | 3 | (8.3) | 11 | (17.1) | 0.21 |